Table 4 Baseline and Follow-up Pathology Data for patients reviewed in the 12-week post hospitilisation COVID-19 virtual clinic
Variable | Baseline Pathology Results | 12-week Pathology Results | ||||||
|---|---|---|---|---|---|---|---|---|
n | Complete Resolution | Persistent Abnormality | p value | n | Complete Resolution | Persistent Abnormality | p value | |
Hb (g/L) | 98 | 132 (118–143) | 136 (126–146) | 0.159 | 97 | 140 (131–147) | 140 (124–147) | 0.793 |
WBC (10 × 9/L) | 98 | 6.7 (5.0–8.3) | 6.8 (4.6–11.4) | 0.616 | 97 | 7.0 (4.5–6.6) | 7.3 (6.1–9.3) | 0.190 |
Neutrophils (10 × 9/L) | 98 | 4.8 (3.6–6.3) | 5.7 (3.7–8.8) | 0.296 | 97 | 3.7 (2.6–4.4) | 4.0 (3.1–5.2) | 0.164 |
Lymphocytes (10 × 9/L) | 98 | 1.0 (0.8–1.2) | 1.0 (0.7–1.5) | 0.882 | 97 | 2.0 (1.6–2.7) | 2.4 (1.8–3.0) | 0.163 |
Sodium (mmol/L) | 96 | 137 (135–140) | 135 (133–138) | 0.007** | 97 | 140 (139–142) | 141 (139–142) | 0.752 |
Urea (mmol/L) | 96 | 4.8 (3.6–6.2) | 6.4 (4.9–7.8) | 0.033* | 96 | 5.5 (4.5–6.6) | 5.9 (4.5–7.2) | 0.402 |
Creatinine (μmol/L) | 96 | 69.5 (57.0–89.8) | 73.5 (60.0–91.5) | 0.724 | 96 | 74 (62–89) | 68 (56–81) | 0.206 |
Ferritin (μg/L) | 80 | 539 (285–1417) | 752 (452–1121) | 0.385 | 50 | 41 (26–82) | 41 (29–107) | 0.807 |
LDH (U/L) | 73 | 679 (502–955) | 957 (697–1193) | 0.006** | 48 | 373 (317–405) | 435 (360–490) | 0.004** |
CRP (mg/L) | 96 | 94 (32–150) | 115 (86–155) | 0.123 | 97 | 2 (1–4) | 3 (1–6) | 0.333 |
HS-Troponin I (ng/L) | 76 | 7 (4–12) | 11 (6–27) | 0.014* | 48 | 3 (2–5) | 3 (3–5) | 0.365 |
ALT (U/L) | 89 | 32 (22–63) | 36 (25–65) | 0.510 | 96 | 22 (18–31) | 21 (13–41) | 0.710 |
Bilirubin (μmol/L) | 77 | 9 (7–12) | 13 (8–18) | 0.015* | 96 | 9 (7–11) | 8 (7–12) | 0.984 |
D-dimer (μg/L) | 59 | 447 (295–811) | 548 (407–734) | 0.257 | 85 | < 230& | < 230& | 0.769 |